|

Breast Cancer Clinical Trials in Oklahoma

55 recruiting studies across 2 cities

Browse by City

Oklahoma City
52 trials
Tulsa
8 trials

All Trials in Oklahoma

Phase
Trial Phase Dist.
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesPhase 1/2<1 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN TrialsN/A<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast CancerN/A<1 mi
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialPhase 1<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3<1 mi
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPhase 2<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsPhase 2<1 mi
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic ChemotherapyEarly 1<1 mi
E-Mindfulness Approaches for Living After Breast CancerPhase 3<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerPhase 3<1 mi
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsPhase 1<1 mi
A Study of XMT-1660 in Participants With Solid TumorsPhase 1<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPhase 3<1 mi
Mobile Health for Adherence in Breast Cancer PatientsN/A<1 mi
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPhase 2<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2<1 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Phase 3<1 mi
Study of AVZO-021 in Patients With Advanced Solid TumorsPhase 1/2<1 mi
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsPhase 1<1 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A<1 mi
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Phase 2<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerPhase 1<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3<1 mi
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid TumorsPhase 1<1 mi
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer—<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainPhase 3<1 mi
A Study of NX-1607 in Adults With Advanced MalignanciesPhase 1<1 mi
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1<1 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
Study of XB010 in Subjects With Solid TumorsPhase 1<1 mi
National Cancer Institute "Cancer Moonshot Biobank"—<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsPhase 1<1 mi
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2<1 mi
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsPhase 1<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPhase 1<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid TumorsPhase 1<1 mi
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasPhase 1<1 mi
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies—<1 mi
The Vanguard Study: Testing a New Way to Screen for CancerN/A<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/2<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3<1 mi
BostonGene and Exigent Genomic INsight Study—<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.